REG - Futura Medical PLC - Directors’ / PDMR Dealing

Futura MedicalAnnouncement

13/09/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240913:nRSM0225Ea&default-theme=true

RNS Number : 0225E  Futura Medical PLC  13 September 2024

13 September 2024

Futura Medical plc

("Futura" or the "Company")

Directors' / PDMR Dealing

Futura Medical plc (AIM: FUM), the consumer healthcare company behind Eroxon,
that specialises in the development and global commercialisation of
innovative and clinically proven sexual health products, announces that it
has received notice to exercise options from James Barder, CEO and Ken James,
executive Head of R&D to exercise 500,000 options over ordinary shares
of 0.2 pence in the Company ("Ordinary Shares").

 

The following options have been exercised:

 

 Director      Number of Options exercised  Status      Exercise price  Total number of Options held following exercise
 James Barder  250,000                      Unapproved  30.50p
 James Barder  50,000                       EMI         15.50p          3,660,927
 Ken James     200,000                      EMI         30.50p          3,455,955

 

James Barder has sold 250,000 Ordinary Shares the proceeds of which will be
used to satisfy the tax liability and the exercise of 50,000 options with an
exercise price of 15.50p, these shares will be retained by James. In addition,
Ken James has sold 200,000 Ordinary Shares.

 

Following these transactions James Barder's interests in Ordinary Shares is
1,470,972 Ordinary Shares, representing approximately 0.5% of the Company's
issued share capital. Ken James' interests in Ordinary Shares of 299,581
Ordinary Shares representing approximately 0.1% of the Company's issued share
capital remains unchanged.

 

450,000 options with an exercise price of 30.50p would lapse on 30 September
2024, if not exercised.

 

Further disclosures are contained in the tables below.

 

Total Voting Rights

 

Following the issue of 500,000 Ordinary Shares under the Company's existing
block listings to satisfy the exercise of options, for the purposes of
the FCA's Disclosure and Transparency Rules, the Company's total issued
share capital at the date of this announcement is 302,363,641 Ordinary
Shares.

Since the Company currently holds no shares in treasury, the total number of
voting rights in the Company is 302,363,641 and this figure may therefore be
used by shareholders as the denominator for the calculations by which they
will determine if they are required to notify their interest in, or a change
to their interest in, the share capital of the Company under
the FCA's Disclosure and Transparency Rules.

 

ENDS

 

Contacts:

 Futura Medical plc              James Barder                                               investor.relations@futuramedical.com

                                                          (mailto:Investor.relations@futuramedical.com)
                                 Chief Executive Officer

                                                          +44 (0)1483 685 670
                                 Angela Hildreth

                                                          www.futuramedical.com (http://www.futuramedical.com/)
                                 Finance Director and COO

 Panmure Liberum                 Emma Earl, Will Goode, Mark Rogers (Corporate Finance)     +44 (0)20 3100 2000

 Nominated Adviser               Rupert Dearden (Corporate Broking)

 and Broker

 Stifel Nicolaus Europe Limited  Alan Selby                                                 +44 (0)207 710 7600

 Joint Broker                    Ben Maddison

 Alma Strategic Communications   Rebecca Sanders-Hewett                                     +44 (0)20 3405 0205

                                 Sam Modlin                                                 futura@almastrategic.com (mailto:futura@almastrategic.com)

                                 Will Ellis Hancock

 

Notes to Editors:

Futura Medical plc (AIM: FUM) is the developer of innovative sexual health
products, including lead product Eroxon. Our core strength lies in our
research, development and commercialisation of topically delivered gel
formulations in sexual health products.

Eroxon, Futura's clinically proven lead product, has been developed for the
treatment of Erectile Dysfunction ("ED"). The highly differentiated product,
which is the only topical gel treatment for ED available over the counter and
helps men get an erection in ten minutes, addresses significant unmet needs
in the ED market.

ED impacts 1 in 5 men globally across all adult age brackets, with
approximately half of all men over 40 experiencing ED and 25% of all new
diagnoses being in men under 40.

Futura has distribution partners in place in a number of major consumer
markets including Haleon in the US, the largest market for ED in the world,
and Cooper Consumer Health in Europe. Eroxon has been nominated for a
number of healthcare industry awards and has won two to-date.

 

 1   Details of the person discharging managerial responsibilities/person closely
     associated
 a)  Name                                                         James Barder
 2   Reason for the notification
 a)  Position/status                                              Chief Executive Officer
 b)  Initial notification/Amendment                               Initial notification
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                         Futura Medical plc
 b)  LEI                                                          21380053QLT46UNV2303
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument   Ordinary shares at 0.2p each

     Identification code                                           GB0033278473
 b)  Nature of the transaction                                     1.    Exercise of options with exercise price of 30.50p

                                                                  2.    Disposal of 250,000 ordinary shares following exercise

                                                                  3.    Exercise of 50,000 options with exercise price of 15.50p

 c)  Price(s) and volume(s)                                       Price(s)  Volume(s)

                                                            1.  30.50p    250,000
                                                                  2.  40.6628p  250,000
                                                                  3.  15.50p    50,000

 
 d)  Aggregated information                                       1. 250,000

     -         Aggregated volume                                  2. 250,000

     -         Price                                              3. 65,000

                                                                  1. £76,250.00

                                                                  2. £101,657.00

                                                                  3. £7,750

 e)  Date of the transaction                                      12 September 24
 f)  Place of the transaction                                     1. Outside a trading venue

                                                                  2. XLON

                                                                  3. Outside a trading venue

 

d)

Aggregated information

-         Aggregated volume

-         Price

1. 250,000

2. 250,000

3. 65,000

 

1. £76,250.00

2. £101,657.00

3. £7,750

 

e)

Date of the transaction

12 September 24

f)

Place of the transaction

1. Outside a trading venue

2. XLON

3. Outside a trading venue

 

 

 1   Details of the person discharging managerial responsibilities/person closely
     associated
 a)  Name                                                         Ken James
 2   Reason for the notification
 a)  Position/status                                              Executive Director

and Head of R&D
 b)  Initial notification/Amendment                               Initial notification
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                         Futura Medical plc
 b)  LEI                                                          21380053QLT46UNV2303
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument  Ordinary shares at 0.2p each

     Identification code                                           GB0033278473
 b)  Nature of the transaction                                    1.    Exercise of options with exercise price of 30.50p

                                                                  2.    Disposal of 200,000 ordinary shares following exercise

 c)  Price(s) and volume(s)                                           Price(s)  Volume(s)

                                                            1.  30.50p    200,000
                                                                  2.  40.6628p  200,000

 
 d)  Aggregated information                                       1. 200,000

     -         Aggregated volume                                  2. 200,000

     -         Price

                                                                  1. £61,000.00

                                                                  2. £81,325.60

 e)  Date of the transaction                                      12 September 2024
 f)  Place of the transaction                                     1. Outside a trading venue

                                                                  2. XLON

 

d)

Aggregated information

-         Aggregated volume

-         Price

1. 200,000

2. 200,000

 

1. £61,000.00

2. £81,325.60

 

e)

Date of the transaction

12 September 2024

f)

Place of the transaction

1. Outside a trading venue

2. XLON

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHSFAFIEELSEDU